How do I evaluate whether chloroprocaine hydrochloride has investable formulation IP?

By checking whether Orange Book-listed patents map to a specific strength/dosage form and whether those patents are active close to expiry, then tying that to pending or resolved ANDA litigation.

What market signal indicates chloroprocaine hydrochloride will face rapid generic pricing compression?

The absence of active, presentation-specific Orange Book patents for key SKUs and the presence of multiple ANDA approvals ready for AB substitution.

What role do stability and impurity specs play in chloroprocaine hydrochloride generic competition?

They can slow approvals, limit interchangeable substitution, and protect incumbents if generics struggle to meet shelf-life and impurity requirements at scale.

Do settlement agreements materially affect chloroprocaine hydrochloride revenue timing?

Yes, they can shift entry dates and reduce uncertainty by creating a delayed, planned launch schedule rather than immediate post-expiry competition.

Is chloroprocaine hydrochloride exposed to biosimilar-type replacement risk?

No, it is not a biologic and does not face biosimilar substitution dynamics.

When will the CHLOROPROCAINE HYDROCHLORIDE patents expire, and when will generic CHLOROPROCAINE HYDROCHLORIDE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	CHLOROPROCAINE HYDROCHLORIDE	chloroprocaine hydrochloride	INJECTABLE;INJECTION	040273-001	Sep 9, 1998	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hospira	CHLOROPROCAINE HYDROCHLORIDE	chloroprocaine hydrochloride	INJECTABLE;INJECTION	087446-001	Apr 16, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hikma	CHLOROPROCAINE HYDROCHLORIDE	chloroprocaine hydrochloride	INJECTABLE;INJECTION	040273-002	Sep 9, 1998	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 8, 2026

Chloroprocaine Hydrochloride Patent Estate, Exclusivity, and Investment Fundamentals: What Investors Need to Know (2026)

Executive summary

Chloroprocaine hydrochloride is an older local anesthetic with limited, drug-like commercial growth potential tied to branded exclusivity. The investment case is driven by (1) whether meaningful IP still exists for specific formulations, delivery systems, and concentration/packaging, and (2) ongoing FDA/market access for injectable local anesthetic products (including hospital group purchasing penetration). Absent active, enforceable IP for particular presentations, the commercial baseline trends toward mature-generic pricing with low incremental upside and execution-heavy margins.

What is chloroprocaine hydrochloride and how is it used clinically?

Chloroprocaine hydrochloride is an ester-type local anesthetic used for procedures requiring local or regional anesthesia. In the US, the dominant market access pathway is via generic injectable products unless a specific presentation is protected.

Key clinical use profiles that shape demand

Procedural anesthesia in surgical and interventional settings (local and regional applications).
Short-acting anesthesia needs, where rapid offset matters for throughput.
Use in hospitals and ambulatory surgery centers where anesthesia supply is standardized and procurement-led.

Delivery form focus that impacts IP and product competition

For investing purposes, the “real” unit of IP is the marketed injectable presentation (concentration, fill volume, container closure, and any preservative system). IP that only covers the drug substance without protection for a given presentation typically loses economic relevance once generics enter.

What patents protect chloroprocaine hydrochloride in the US?

Chloroprocaine hydrochloride’s earliest composition IP has largely aged out in most markets, shifting the patent estate focus to:

formulation patents (buffers, stabilizers, pH systems, preservative systems),
method-of-use patents (specific indications or dosing regimens, if any are still asserted),
packaging/container patents (less common but can matter for stability),
manufacturing process patents (purification, impurity control, or sterilization steps).

Typical patent estate structure for older injectables (investor lens)

Composition of matter for the active is usually expired.
Active-protection windows concentrate in:
- specific concentration strengths (for example, a narrow set of injectable strengths),
- ready-to-use versus multi-dose packaging,
- preservative-free variants (if marketed),
- stability-improved formulations that support shelf-life claims.

Practical IP implication

For investment screening, the question is not “is chloroprocaine patented?” but “which chloroprocaine presentations still have enforceable, US-relevant Orange Book listings and/or pending or active Hatch-Waxman litigation.”

What is the Orange Book status of chloroprocaine hydrochloride products?

Orange Book status typically determines the investable layer:

Whether there are active patents listed for a given NDA product,
Whether those patents are nearing expiration,
Whether any listed patents correspond to formulation or method-of-use.

Investor interpretation framework

If Orange Book shows no active patents: the product is likely already in mature generic competition.
If Orange Book shows active formulation or use patents: it can create leverage for exclusivity via exclusivity terms, forfeiture risks, and settlement dynamics.

Why Orange Book drives valuation

Local anesthetic injectable economics are procurement-led. A single active formulation patent can support premium pricing if it blocks AB-rated equivalents for a specific presentation.

When does chloroprocaine hydrochloride lose exclusivity and how do patent expirations map to generic entry?

For older injectables, exclusivity usually matters only when tied to:

a still-active NDA reconfiguration (new formulation, new presentation),
a still-active regulatory exclusivity (rare for older entries unless a reformulation is protected),
or litigation that delays effective generic launch.

Timelines investors should model (US Hatch-Waxman logic)

Patent expiration for Orange Book-listed patents for the specific strength and dosage form.
Any “grace” effects from 30-month stays or injunctions triggered by Paragraph IV challenges.
End of 180-day exclusivity if applicable to a first-filer ANDA.
FDA approval and launch timing post-stay.

Core investment point

If active patents are absent at the presentation level, “exclusivity modeling” collapses to generic pricing curves and competitive capacity dynamics.

Are there Paragraph IV challenges or patent litigation affecting chloroprocaine hydrochloride?

For an investable view, litigation status is the gating variable that can:

delay generic competition,
create licensing/settlement cash flow,
or invalidate claimed patents.

What tends to matter for chloroprocaine

Litigation tends to cluster around formulation stability, pH/buffer systems, preservative systems, and impurity profiles rather than the active molecule itself.
Local anesthetics are typically low patent runway unless a late-life reformulation exists.

Commercial impact mechanism

If an ANDA is stayed via Paragraph IV litigation, branded or incumbent sellers can preserve share and pricing temporarily.
If a court narrows or invalidates key formulation claims, generic launch risk rises quickly.

What formulations are protected by chloroprocaine hydrochloride patents?

Where IP remains, it often protects:

pH and buffering systems that stabilize the ester local anesthetic against hydrolysis,
impurity profile limits and manufacturing controls tied to stability,
preservative system composition or absence (preservative-free variants),
concentration-specific formulations that enable shelf-life and usability.

Why formulation matters more than substance patents

Generic developers can often replicate the chemical entity while changing formulation details. If the incumbent’s value proposition is shelf-life and stability under realistic handling, then formulation IP can protect market share even after composition expiry.

How does chloroprocaine hydrochloride compare with other local anesthetics for investment relevance?

Investment comparables include other short-acting ester or amide local anesthetics used in procedural anesthesia.

Competitive dimensions that drive pricing and volume

Product availability and hospital formulary positioning.
Shelf-life, handling, and stability.
Price and rebate economics within group purchasing.
Supply reliability and manufacturing scalability.

Investor takeaway

If chloroprocaine is competing in a heavily substitutable local anesthetic bucket, incremental IP value must translate into restricted AB substitution for a specific presentation to sustain premium economics.

Biosimilar risk and biologics exposure: does it apply to chloroprocaine?

No. Chloroprocaine hydrochloride is a small-molecule local anesthetic with no biosimilar pathway.

Which companies produce chloroprocaine hydrochloride injectable products in the US?

For investment diligence, company exposure must be mapped by:

which NDA holders own the marketed products,
which ANDA filers compete by strength and container type,
and whether there are “authorized generic” dynamics.

What to model

Market concentration by presentation.
Whether a small set of generics dominate hospital volume.
Manufacturing capacity and supply continuity risks.

What is the commercial opportunity and revenue exposure for chloroprocaine hydrochloride?

Chloroprocaine hydrochloride’s revenue profile is typically:

mature and volume-led,
sensitive to procurement and price resets,
constrained by substitution and generic penetration.

Where value can still concentrate

Protected presentations (if any active Orange Book patents exist).
Stability-optimized formulations that are preferred on formulary.
Limited-supply situations or manufacturing constraints that keep certain strengths from being aggressively competed.

Investment implication

Upside is most plausible in a scenario where:

there is an enforceable formulation patent tied to a key hospital-ready presentation,
competitors face launch delays,
or supply disruptions enable temporary pricing support.

How strong is the patent estate for chloroprocaine hydrochloride?

For an older local anesthetic, patent strength is usually medium to low at the drug-substance level and only becomes investable if:

formulation or method-of-use patents remain in-force,
or litigation is ongoing that blocks at-scale generic entry.

Patent strength scoring rubric (investor use)

In-force status: remaining time until expiry.
Claim scope: formulation-specific versus broad.
Enforcement likelihood: presence of active ANDA litigation.
Presentation criticality: whether the protected strength is a high-volume SKU.

What generic entry risks exist for chloroprocaine hydrochloride?

Generic entry risk is primarily:

timing-driven by remaining patent and exclusivity,
and competitive-driven by number of filers with scalable manufacturing.

Typical generic launch pressure pattern

Once protection ends for a presentation, AB-rated generics can replace branded or incumbent supply quickly.
Price competition then compresses margins unless the incumbent has cost advantages or retains protected niches.

How do manufacturing and IP barriers affect chloroprocaine hydrochloride market competition?

Even with “substance freedom,” practical barriers include:

stability against ester hydrolysis,
impurity control,
maintaining pH/buffer and packaging compatibility,
sterile injectable quality systems and batch consistency.

Investor angle

If the incumbent has superior manufacturing validation for shelf-life and impurity specs, some generic entrants may face delayed approvals or quality-led recalls that temporarily protect share.

What does an investment scenario for chloroprocaine hydrochloride look like?

Investment cases for chloroprocaine hydrochloride generally fall into two buckets:

Scenario 1: Patent-protected niche presentation still active

Logic

Orange Book lists active patents tied to a specific strength/presentation.
Competitors face delays via litigation or settlement. What to underwrite
Market share protection through the remaining exclusivity/patent window.
Pricing resilience versus rapid AB substitution.
Evidence that the protected SKU is high volume or formulary-critical.

Scenario 2: No active protectable presentation-specific IP